The data, math, and limitations behind Regimen's half-life visualizer and PK curves — and why they help you get more from your protocol.
When you inject a compound, your body absorbs and eliminates it over time. The question every protocol user wants answered is: "What are my levels doing between doses?"
Blood work gives you a snapshot — one point in time. Regimen's PK curves give you the full picture between blood draws. They show you:
This isn't a replacement for blood work — it's a tool that helps you understand your protocol and have better conversations with your healthcare provider.
Regimen's half-life visualizer and in-app PK curves show estimated medication levels over time for injectable compounds.
when levels are highest after injection
when levels are lowest before your next dose
how repeated dosing at regular intervals builds to a stable concentration range
when tracking multiple compounds, see how their profiles interact on the same timeline
Regimen uses a one-compartment, first-order elimination model — the most widely used pharmacokinetic model for depot (injected) medications.
The core equation
C(t) = (D / Vd) × e(-k × t)
C(t) = estimated concentration at time t
D = dose administered
Vd = volume of distribution
k = elimination rate constant (derived from half-life: k = ln(2) / t½)
t = time since administration
For repeated dosing, the model applies superposition — each new dose adds to the remaining concentration from previous doses, converging toward a steady-state range after approximately 4-5 half-lives.
What this means in practice: If you inject testosterone cypionate (half-life ~8 days) every 3.5 days, the model shows how each injection builds on residual levels from the previous dose, eventually reaching a stable peak-trough range. This helps you understand WHY splitting your dose into more frequent injections creates more stable levels.
Half-life values used in Regimen's models come from:
For research peptides (BPC-157, TB-500, ipamorelin, etc.), published human PK data is often limited. In these cases, Regimen uses available animal model PK data, established community protocols where clinical data is absent, and conservative estimates when multiple sources disagree. All half-life values are documented in our half-life data reference.
These are estimates, not blood tests. PK curves show what standard pharmacokinetic models predict for a given dose and schedule. They do not account for:
Metabolism, body composition, injection site, injection technique, and genetics all affect how your body absorbs and eliminates compounds. Two people on the same protocol will have different actual blood levels.
Subcutaneous vs. intramuscular injection, carrier oil formulation, injection depth, and absorption rate all affect actual concentrations.
The PK model treats each compound independently. It does not model how compounds may influence each other's effective levels.
Some compounds at some doses may exhibit saturable metabolism. The one-compartment first-order model assumes linear kinetics.
Compounded medications may vary in potency and formulation quality between sources. PK models assume the labeled dose is accurate.
The PK visualizer is a tracking tool. It helps you understand the general shape of your dosing curves, compare injection frequencies, and visualize steady-state concepts. It is not a diagnostic tool and should not be used to make medical decisions without consulting your healthcare provider.
When we find better PK data, correct an error, or add a new compound:
We update the half-life value in our database
We document the change in our half-life data reference
Existing PK visualizations update automatically with the corrected data
We do not backdate or alter historical dose logs — your tracking data stays exactly as you logged it
If you find a half-life value that seems wrong, or if you know of a published PK study we haven't incorporated, please email us at support@helloregimen.com with the source. We review and update our data regularly.
Your protocol deserves better than a notes app and a calendar.